Liposomal Daunorubicin + Cytarabine: Enhanced Synergistic Antineoplastic Effect in AML Treatment
Interview: There is a critical need for more effective therapies, as current treatment strategies still fall short of achieving long-term disease control in a substantial proportion of patients.
In this interview, Dr. Andrea Lenartova, senior hematologist at Oslo University Hospital and specialist in AML, shares her insights into the newly approved therapy.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
